Serial Number
97936772
Owner
Genmab A/SAttorney
Max VernFirst Use Date
May 31, 2023
Filing Date
May 15, 2023
MYNAVCARE PATIENT SUPPORT Trademark
Serial Number: 97936772 • Registration: 7819913
Trademark Classes
Class 36 - Insurance & Financial
Insurance; financial affairs; monetary affairs; real estate affairs
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Class 45 - Legal & Security Services
Legal services; security services for the protection of property and individuals
Class 35 - Advertising & Business
Advertising; business management; business administration; office functions
Owner Contact Info
Legal Representation
Correspondence Address
Max Vern Amster, Rothstein & Ebenstein LLP
405 Lexington Avenue
New York, NY 10174
United States
Trademark Details
Filing Date
May 15, 2023
Registration Date
June 3, 2025
First Use Anywhere
May 31, 2023
First Use in Commerce
May 31, 2023
Published for Opposition
March 19, 2024
Goods & Services
Financial administration of patient reimbursement and patient financial assistance programs, namely reimbursement payment processing in the field of pharmaceutical and medical claims; Charitable services, namely, providing financial support to disadvantaged patients for the purpose of reimbursing medical and pharmaceutical expenses; Providing counseling and consulting in the field of healthcare insurance benefits in connection with patient reimbursement and patient financial assistance programs; Providing information about healthcare insurance plans, patient financial assistance, and patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
Provision of consumer information in the field of patient reimbursement and medical benefit support; Business administrative services for medical referrals in connection to patient reimbursement programs; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
Providing personal support services for patients and families of patients in connection to disease management and navigation through medical treatments, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders in connection to disease management and reimbursement of medical expenses, namely, companionship, help with medical forms, emotional counseling and emotional support; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries
Medical assistance, namely disease management programs; provision of health care information in connection to disease management and navigation through medical treatments; provision of medical information in connection with health conditions and treatment of these conditions; medical counseling for patients in connection with disease management; Consultancy in the field of the medical treatment of cancer, autoimmune diseases, and inflammatory disorders; providing information to patients and families of patients in the field of administering medication and choosing treatments; providing a website featuring information in the medical and health fields in connection to disease management and navigation through medical treatments; health care services, namely disease management programs; medical and pharmaceutical consultation in connection to disease management; medical services, namely, provision of medical information for supporting patients in relation to the reimbursement of medical expenses; Providing a web site featuring medical information for patients in relation to the reimbursement of medical expenses; all in the field of treatment with monoclonal antibody anticancer medications; none of the above aimed at Massachusetts seniors who are Medicaid/MassHealth beneficiaries or are dual-eligible Medicare and Medicaid/MassHealth beneficiaries